Regeneron Pharmaceuticals, Inc.

Brinda Prasad

Andrew J Murphy

Karolina Meagher

Lynn Macdonald

Christos Kyratsous

Sean Stevens

Cagan Gurer

Peter W Mason

Naxin Tu

Vera Voronina

Chia-Yang Lin

Alida Coppi

Anna Zumsteg

According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the target antigen with an ECof about 10 nM or less, and/or are capable of promoting complement deposition on the target antigen with an ECof about 10 nM. In certain embodiments, the bispecific antigen-binding molecules of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of an infectious agent or cancer cell is desired and/or therapeutically beneficial.

Compositions and methods for using bispecific antibodies to bind complement and a target antigen

Disclosed herein are genetically modified rodent animals comprising in their genome a nucleic acid which comprises a nucleotide sequence encoding a human CR1 polypeptide, wherein the rodent animals display a human-like expression of the human CR1 polypeptide. Also disclosed herein are isolated rodent cells including rodent embryonic stem cells, and rodent tissues. Further disclosed are nucleic acid vectors and methods for making the genetically modified rodent animals, as well as methods of using such genetically modified rodent animals for screening and testing candidate compounds.

Rodent animals expressing human CR1

Speciated antibodies or antigen-binding fragments that bind staphylococcal antigens are provided, where the antibodies and antigen-binding fragments have attenuated Fc binding to Protein A or homologous protein. Compositions comprising the antibodies and methods of use are also provided. The antibodies and compositions are useful for treating staphylococcal infection, reducing serum or kidney bacterial titers, and treating symptoms associated with staphylococcal infection. The antibodies may also prevent the severity and/or duration of the primary disease.

Anti-antibodies and uses thereof

Disclosed herein are nucleic acids encoding for and proteins expressing chimeric C1q polypeptides, non-human animals comprising said nucleic acids, and methods of making or using said non-human animals.

Non-human animals expressing humanized C1Q complex

According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds aspecies target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to thespecies target antigen with an ECof about 10 nM or less, and/or are capable of promoting complement deposition on thespecies with an ECof about 10 nM. The antibodies of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of aspecies is desired and/or therapeutically beneficial, for example, for treating staphylococcal infections including a skin infection, cellulitis, pneumonia, meningitis, urinary tract infection, toxic shock syndrome, endocarditis, osteomyelitis, bacteremia, or sepsis, or for preventing or treating ainfection that occurs as a result of a surgical procedure.

Growing community of inventors

Long Island City, NY, United States of America

Brinda Prasad